 The FDA has signed off Turning Point Therapeutics Incs NASDAQ: TPTX Investigational New Drug IND application for elzovantinib aumolertinib combo therapy in EGFR mutant MET-amplified advanced non-small cell lung cancer NSCLC. The Company expects to initiate the Phase 1b2 SHIELD-2 combination study in mid-2022. 